Latest Breast Cancer Screening News

BCAL Diagnostics has launched a $10 million convertible note facility, with $5 million already committed, to strengthen its capital position and accelerate commercialisation of its cancer detection technologies.

Rhythm Biosciences has formalised a strategic co-marketing partnership with the Know Your Lemons Foundation to promote its geneType Breast Cancer Risk Assessment Test, expanding access to early detection tools for women in the US and Australia.

BCAL Diagnostics has partnered with Sonic Healthcare Australia to broaden access to its innovative blood-based breast cancer test, BREASTEST plus™, across Sydney. This move formalizes a commercial rollout following successful trials and aims to improve early detection for women with dense breast tissue.

BCAL Diagnostics has secured a strategic partnership with Cancer Care Associates to fast-track the clinical adoption and revenue generation of its innovative BREASTEST plus™ breast cancer blood test starting FY2026.

Rhythm Biosciences’ subsidiary Genetype has landed a pivotal 12-month contract with the University of Melbourne to provide advanced breast cancer risk assessments, marking a significant step in personalised cancer screening.